At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Tocilizumabdrug
Likely dose
Tocilizumab 8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of the Efficacy and Safety of Tocilizumab for Treatment of Inflammation in the Renal Allograft
In Brief
A Phase 2 clinical trial evaluating Tocilizumab for Late Complication From Kidney Transplant. Completed, enrolled 33 participants across 1 site.
Detailed Summary
Randomized open label clinical trial in which 48 renal transplant recipients with inflammation in the 6 month allograft biopsy will either continue usual immunosuppression or receive monthly Actemra (Tocilizumab) infusions for 6 months in addition to usual immunosuppression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLate Complication From Kidney Transplant
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartJun 2014
Primary CompletionDec 2018
TodayJul 2026
First PostedApr 9, 2014
Enrollment StartJun 1, 2014
Primary CompletionDec 16, 2018
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 12.2 years ago
Interventions
Tocilizumabdrug
Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.